CoChat
Sign Up
Cited by 155Nanoparticle-Based Drug DeliveryAdvanced Drug Delivery SystemsDendrimers and Hyperbranched Polymers

The DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.

Poly(Ethylene Glycol)–Polylactide Micelles for Cancer Therapy

Open access
Wang, Jixue, Li, Shengxian, Han, Yuping, Guan, Jingjing, Chung, Shirley, Wang, Chunxi, Li, Di·2018·Frontiers in Pharmacology
DOI 10.3389/fphar.2018.00202PMC PMC5890116
Open this paper in CoChat — free accountOpen PDF

Abstract

For the treatment of malignancy, many therapeutic agents, including small molecules, photosensitizers, immunomodulators, proteins and genes, and so forth, have been loaded into nanocarriers for controllable cancer therapy. Among these nanocarriers, polymeric micelles have been considered as one of the most promising nanocarriers, some of which have already been applied in different stages of clinical trials. The successful advantages of polymeric micelles from bench to bedside are due to their special core/shell structures, which can carry specific drugs in certain disease conditions. Particularly, poly(ethylene glycol)-polylactide (PEG-PLA) micelles have been considered as one of the most promising platforms for drug delivery. The PEG shell effectively prevents the adsorption of proteins and phagocytes, thereby evidently extending the blood circulation period. Meanwhile, the hydrophobic PLA core can effectively encapsulate many therapeutic agents. This review summarizes recent advances in PEG-PLA micelles for the treatment of malignancy. In addition, future perspectives for the development of PEG-PLA micelles as drug delivery systems are also presented.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fphar.2018.00202

Cites

115 of 115 references verified0 citation errors · 0 not checkable

Statistics

Figures

Scheme 1 Schematic illustration of PEG-b-PLA micelle in application of antitumor. Reproduced with permission from Cho et al. (2016); Peng et al. (2016); Wang et al. (2016); Moy and Tunnell (2017); Yin et al. (2017) and Zhai et al. (2017).
Scheme 1 Schematic illustration of PEG-b-PLA micelle in application of antitumor. Reproduced with permission from Cho et al. (2016); Peng et al. (2016); Wang et al. (2016); Moy and Tunnell (2017); Yin et al. (2017) and Zhai et al. (2017).CC BY · PubMed Central
Figure 1 (A) Schematic illustration of synthesis of mPEG–PLA-docetaxel polymer drug conjugate. (B) The in vitro release of DTX from DTX-PM (PBS, pH 7.4 and pH 5.0, at 37 °C). (C) Tumor volume of free DTX and DTX-PM in xenograft tumor model (***P < 0.0001). Reproduced with permission from Shi et al. (2016).
Figure 1 (A) Schematic illustration of synthesis of mPEG–PLA-docetaxel polymer drug conjugate. (B) The in vitro release of DTX from DTX-PM (PBS, pH 7.4 and pH 5.0, at 37 °C). (C) Tumor volume of free DTX and DTX-PM in xenograft tumor model (***P < 0.0001). Reproduced with permission from Shi et al. (2016).CC BY · PubMed Central
Figure 2 (A) Schematic illustration of the preparation and their cellular action process of TPT-TT NPs. (B) TEM image (Scale bar 500 nm) and size distribution determined by DLS of TPT-TT NPs. (C) Photothermal conversion behavior of TPT-TT NPs at various concentrations. (D) Relative cell viabilities of HepG2 cells incubated with different concentrations of TPT-TT NPs. Reproduced with permission from Sun et al. (2015).
Figure 2 (A) Schematic illustration of the preparation and their cellular action process of TPT-TT NPs. (B) TEM image (Scale bar 500 nm) and size distribution determined by DLS of TPT-TT NPs. (C) Photothermal conversion behavior of TPT-TT NPs at various concentrations. (D) Relative cell viabilities of HepG2 cells incubated with different concentrations of TPT-TT NPs. Reproduced with permission from Sun et al. (2015).CC BY · PubMed Central
Figure 3 (A) Structure, characterization, and optical properties of cRGD-NEt2Br2BDP. (B) NPTEM image of cRGD-NEt2Br2BDP NP. Inset: size distribution of cRGD-NEt2Br2BDP NP determined with DLS. (C) pH titration curves of fluorescence intensity of different NPs. (D) In vivo PDT and therapeutic monitoring on subcutaneous U87MG tumor-bearing mice with cRGD-NEt2Br2BDP NP. Reproduced with permission from Tian et al. (2015).
Figure 3 (A) Structure, characterization, and optical properties of cRGD-NEt2Br2BDP. (B) NPTEM image of cRGD-NEt2Br2BDP NP. Inset: size distribution of cRGD-NEt2Br2BDP NP determined with DLS. (C) pH titration curves of fluorescence intensity of different NPs. (D) In vivo PDT and therapeutic monitoring on subcutaneous U87MG tumor-bearing mice with cRGD-NEt2Br2BDP NP. Reproduced with permission from Tian et al. (2015).CC BY · PubMed Central
Figure 4 Analysis of T cell immunity. (A) Cytokine secretion responses and (B,C) mRNA expression levels. Antitumor efficacy of OVA protein formulated with different adjuvants and administered to C57BL/6 mice bearing EG7 tumor cells. Statistical significance was determined by performing ANOVA followed by a Bonferroni post-test. *p < 0.05. (D) Tumor volume *p < 0.05 compared with no adjuvant group and (E) survival rate. Reproduced with permission from Coumes et al. (2015).
Figure 4 Analysis of T cell immunity. (A) Cytokine secretion responses and (B,C) mRNA expression levels. Antitumor efficacy of OVA protein formulated with different adjuvants and administered to C57BL/6 mice bearing EG7 tumor cells. Statistical significance was determined by performing ANOVA followed by a Bonferroni post-test. *p < 0.05. (D) Tumor volume *p < 0.05 compared with no adjuvant group and (E) survival rate. Reproduced with permission from Coumes et al. (2015).CC BY · PubMed Central
Figure 5 (A) Schematic illustration of biodegradable cationic micelles for delivering siRNA into cancer cells. (B) siRNA-positive cells after treated with different FAM-siRNA formulations. (C) Confocal microscopic observation of EGFR silencing effect in MCF-7 cells. Reproduced with permission from Zhao et al. (2012).
Figure 5 (A) Schematic illustration of biodegradable cationic micelles for delivering siRNA into cancer cells. (B) siRNA-positive cells after treated with different FAM-siRNA formulations. (C) Confocal microscopic observation of EGFR silencing effect in MCF-7 cells. Reproduced with permission from Zhao et al. (2012).CC BY · PubMed Central
Figure 6 (A) Preparation of Cur/MPEG–PLA micelles. (B) In vitro release study and (C) representative images of subcutaneous tumors in each treatment group. Reproduced with permission from Zheng et al. (2016).
Figure 6 (A) Preparation of Cur/MPEG–PLA micelles. (B) In vitro release study and (C) representative images of subcutaneous tumors in each treatment group. Reproduced with permission from Zheng et al. (2016).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 115 references

Research works printed but not linked: 2

  1. Das, 2016, Silencing the disease messengers: progress and prospects in developing nucleic acid based therapeutics, RNAi Technol., 5, 85
  2. Huang, 2011, Vaccine Delivery Systems Based on Amphiphilic Bioresorbable Polymers and Their Role in Vaccine Immunogenicity

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Wang, J., Li, S., Han, Y., Guan, J., Chung, S., Wang, C., & Li, D.
Affiliations
  • Chinese Academy of Sciences (CN)
  • Jilin University (CN)
  • First Hospital of Jilin University (CN)
  • University of Waterloo (CA)
Corresponding author
  • Han, Yuping
  • Guan, Jingjing
  • Li, Di
ORCID
Venue
Frontiers in Pharmacology
Publisher
Frontiers Media SA
Published
2018-03-08
Volume
9
Pages
202-202
ISSN
1663-9812 (ISSN-L)
DOI
10.3389/fphar.2018.00202
PMC
PMC5890116
OpenAlex
W2792803144
Cited by
155
References
115
Citations by year
2026: 7 · 2025: 13 · 2024: 26 · 2023: 21 · 2022: 22 · 2021: 20 · 2020: 24 · 2019: 16 · 2018: 5
FWCI
1.07
Type
journal article
Language
en
Open access
Licence
Locations
  • Frontiers in Pharmacology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Natural Science Foundation of China (51673190, 51603204, 51303174, 51473165, 51390484, 51520105004)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
  • Physical Sciences › Materials Science › Polymers and Plastics › Dendrimers and Hyperbranched Polymers
Keywords
polymeric micelles, cancer therapy, drug delivery systems, nanocarriers, core-shell structure, PEGylation, blood circulation, protein adsorption resistance, photosensitizers, gene delivery, clinical translation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review